Trial · NCT00418886
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) in the Overall Population | Vandetanib Plus Pemetrexed | 17.6 | 95% Confidence Interval 13.4 to 18.9 | weeks | |
| Progression-Free Survival (PFS) in the Overall Population | Placebo Plus Pemetrexed | 11.9 | 95% Confidence Interval 11.4 to 15.9 | weeks | |
| Progression-Free Survival in the Female Population | Vandetanib Plus Pemetrexed | 17.9 | 95% Confidence Interval 14.7 to 22.7 | weeks | |
| Progression-Free Survival in the Female Population | Placebo Plus Pemetrexed | 13.0 | 95% Confidence Interval 11.1 to 17.7 | weeks | |
| Overall Survival (OS) | Vandetanib Plus Pemetrexed | 10.5 | 95% Confidence Interval 8.9 to 12.3 | months | |
| Overall Survival (OS) | Placebo Plus Pemetrexed | 9.2 | 95% Confidence Interval 7.1 to 12.0 | months | |
| Objective Response Rate (ORR) | Vandetanib Plus Pemetrexed | 19.1 | percentage of participants | ||
| Objective Response Rate (ORR) | Placebo Plus Pemetrexed | 7.9 | percentage of participants | ||
| Disease Control Rate (DCR) | Vandetanib Plus Pemetrexed | 56.6 | percentage of participants | ||
| Disease Control Rate (DCR) | Placebo Plus Pemetrexed | 45.7 | percentage of participants | ||
| Duration of Response (DoR) | Vandetanib Plus Pemetrexed | 24.1 | 95% Confidence Interval 17.4 to 30.0 | weeks | |
| Duration of Response (DoR) | Placebo Plus Pemetrexed | 24.4 | 95% Confidence Interval 18.0 to 32.0 | weeks | |
| Time to Deterioration of Disease-Related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score | Vandetanib Plus Pemetrexed | 18.1 | 95% Confidence Interval 15.1 to 23.6 | weeks | |
| Time to Deterioration of Disease-Related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score | Placebo Plus Pemetrexed | 12.1 | 95% Confidence Interval 9.7 to 17.3 | weeks | |
| Time to Deterioration of Disease-Related Symptoms by Average Symptom Burden Index (ASBI) Score | Vandetanib Plus Pemetrexed | 16.0 | 95% Confidence Interval 14.0 to 20.3 | weeks | |
| Time to Deterioration of Disease-Related Symptoms by Average Symptom Burden Index (ASBI) Score | Placebo Plus Pemetrexed | 13.4 | 95% Confidence Interval 10.3 to 17.9 | weeks | |
| Longitudinal Analysis of Lung Cancer Symptom Scale Total Score | Vandetanib Plus Pemetrexed | 25.7 | Standard Error 2.85 | mms on a visual analogue scale | |
| Longitudinal Analysis of Lung Cancer Symptom Scale Total Score | Placebo Plus Pemetrexed | 28.3 | Standard Error 2.77 | mms on a visual analogue scale | |
| Longitudinal Analysis of Average Symptom Burden Index Score | Vandetanib Plus Pemetrexed | 21.7 | Standard Error 2.75 | mms on a visual analogue scale | |
| Longitudinal Analysis of Average Symptom Burden Index Score | Placebo Plus Pemetrexed | 24.3 | Standard Error 2.67 | mms on a visual analogue scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00418886/results